Additive protection induced by mixed virus-like particles presenting respiratory syncytial virus fusion or attachment glycoproteins

This publication has 31 references indexed in Scilit:

• Long-Term and Memory Immune Responses in Mice against Newcastle Disease Virus-Like Particles Containing Respiratory Syncytial Virus Glycoprotein Ectodomains
  Journal of Virology, 2012
• The Natural History of Respiratory Syncytial Virus in a Birth Cohort: The Influence of Age and Previous Infection on Reinfection and Disease
  American Journal of Epidemiology, 2012
• Hospitalizations Associated With Influenza and Respiratory Syncytial Virus in the United States, 1993–2008
  Clinical Infectious Diseases, 2012
• Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention
  Proceedings of the National Academy of Sciences, 2012
• Viruslike Particle Vaccine Induces Protection Against Respiratory Syncytial Virus Infection in Mice
  The Journal of Infectious Diseases, 2011
• Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok®) against influenza in healthy adults: A randomized, placebo-controlled trial
  Vaccine, 2011
• Differential Pathogenesis of Respiratory Syncytial Virus Clinical Isolates in BALB/c Mice
  Journal of Virology, 2011
• Assembly and Immunological Properties of Newcastle Disease Virus-Like Particles Containing the Respiratory Syncytial Virus F and G Proteins
  Journal of Virology, 2011
• Biological challenges and technological opportunities for respiratory syncytial virus vaccine development
  Immunological Reviews, 2010
• Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease
  Nature Medicine, 2008